Beta Bionics
Automated insulin delivery system revolutionizes diabetes management with AI-driven decision-making technology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
* | N/A | $204m | IPO |
| Total Funding | 000k | ||
Related Content
Beta Bionics has developed the iLet Bionic Pancreas, an innovative insulin delivery system that aims to simplify and improve diabetes management. This groundbreaking device uses artificial intelligence to automatically calculate and administer insulin doses based on real-time glucose data from continuous glucose monitors.
The iLet system integrates with popular CGM devices like Dexcom and FreeStyle Libre 3 Plus, learning the user's insulin needs over time. Unlike traditional insulin pumps, the iLet eliminates the need for manual carb counting and correction doses, making diabetes management less burdensome for patients.
Beta Bionics recently introduced a color version of the iLet, featuring a brighter display and enhanced user interface. This update improves the visibility of glucose levels, meal announcements, and alerts, further enhancing the user experience.
The company's mission is to reduce the cognitive burden of diabetes management while improving overall glycemic control. By automating insulin delivery decisions, the iLet Bionic Pancreas represents a significant step forward in diabetes care technology, potentially improving the quality of life for millions of people living with diabetes.